PerkinElmer to acquire Oxford Immunotec for USD 22.00 per share in cash Transaction expected to be completed in the first half of 2021 WALTHAM, Mass. & LONDON–(BUSINESS WIRE)–Jan. 7, 2021– PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Oxford Immunotec Global PLC (NASDAQ: OXFD) (“Oxford Immunotec” or the “Company”) are pleased to announce they have reached an... Read more
Agreement includes payment of $27.5 million to Oxford, royalty-free license to QIAGEN and dismissal of all pending litigation Germantown, Maryland, and Hilden, Germany, December 15, 2017 – QIAGEN N.V. (NASDAQ: QGEN, Frankfurt Stock Exchange: QIA) and Oxford Immunotec Ltd. (NASDAQ: OXFD) announced today that they have reached a settlement in the lawsuit in the U.S. District... Read more
OXFORD, United Kingdom and MARLBOROUGH, Mass., September 27, 2017 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced a decision of the U.S. District Court for the District of Massachusetts in the Company’s patent infringement... Read more